Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abattis Bioceuticals Corp (ATT.CN)

Abattis Bioceuticals Corp (ATT.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 32,516
  • Shares Outstanding, K 477,804
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 1.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.47
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings 0.00 on 06/30/19
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.070 +14.29%
on 02/01/19
0.095 -15.79%
on 01/03/19
unch (unch)
since 12/31/18
3-Month
0.060 +33.33%
on 12/06/18
0.140 -42.86%
on 11/07/18
-0.050 (-38.46%)
since 11/01/18
52-Week
0.060 +33.33%
on 12/06/18
0.445 -82.02%
on 02/09/18
-0.365 (-82.02%)
since 02/01/18

Most Recent Stories

More News
Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates

VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd....

ATTBF : 0.0176 (+4.76%)
ATT.CN : 0.080 (unch)
Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates

Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTC: ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into...

ATT.CN : 0.080 (unch)
ATTBF : 0.0176 (+4.76%)
Abattis Announces Resignation of Directors

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - (CSE: ATT) (OTC Pink: ATTBF) (the "" or "") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James...

ATTBF : 0.0176 (+4.76%)
ATT.CN : 0.080 (unch)
Abattis Provides Update on Trading Halt and Announces Management Conference Call

Abattis Bioceuticals Corp (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to provide the following update on the Company's recent trading halt and upcoming conference call with Company management...

ATT.CN : 0.080 (unch)
ATTBF : 0.0176 (+4.76%)
IIROC Trading Halt - ATT

The following issues have been halted by IIROC:

ATT.CN : 0.080 (unch)
Abattis Removed From BCSC Temporary Order

Abattis Bioceuticals Corp (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission ("BCSC"), issued on November...

ATT.CN : 0.080 (unch)
ATTBF : 0.0176 (+4.76%)
Abattis Enters Into Definitive Share Exchange Agreement With NutriVida

Abattis Bioceuticals Corp (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share...

ATT.CN : 0.080 (unch)
ATTBF : 0.0176 (+4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 0.087
1st Resistance Point 0.083
Last Price 0.080
1st Support Level 0.073
2nd Support Level 0.067

See More

52-Week High 0.445
Fibonacci 61.8% 0.298
Fibonacci 50% 0.252
Fibonacci 38.2% 0.207
Last Price 0.080
52-Week Low 0.060

See More

Business Summary

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar